Callan Family Office LLC Invests $340,000 in Charles River Laboratories International, Inc. $CRL

Callan Family Office LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 2,243 shares of the medical research company’s stock, valued at approximately $340,000.

Other hedge funds have also recently modified their holdings of the company. Brooklyn Investment Group raised its position in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares during the last quarter. Cromwell Holdings LLC raised its position in shares of Charles River Laboratories International by 542.9% during the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after purchasing an additional 152 shares during the last quarter. HM Payson & Co. acquired a new position in shares of Charles River Laboratories International during the 1st quarter worth about $31,000. Family Legacy Financial Solutions LLC acquired a new position in shares of Charles River Laboratories International during the 2nd quarter worth about $71,000. Finally, ORG Wealth Partners LLC raised its position in shares of Charles River Laboratories International by 49.8% during the 2nd quarter. ORG Wealth Partners LLC now owns 496 shares of the medical research company’s stock worth $77,000 after purchasing an additional 165 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $170.94 on Thursday. The firm has a 50 day simple moving average of $159.76 and a 200-day simple moving average of $147.90. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The stock has a market cap of $8.41 billion, a price-to-earnings ratio of -128.53, a price-to-earnings-growth ratio of 4.55 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $983.76 million. During the same quarter in the prior year, the company posted $2.80 EPS. The business’s revenue for the quarter was up .6% on a year-over-year basis. On average, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

CRL has been the subject of several research analyst reports. Wall Street Zen upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Barclays upgraded shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $165.00 to $195.00 in a research report on Thursday, October 2nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. Finally, Jefferies Financial Group raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and upped their price objective for the company from $142.00 to $195.00 in a research note on Tuesday, September 9th. Eight equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $179.93.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the completion of the sale, the executive vice president owned 24,116 shares of the company’s stock, valued at $3,800,681.60. This represents a 3.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.30% of the stock is currently owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).